Mylan launches drug for HIV patients

G Naga Sridhar Hyderabad | Updated on January 09, 2018


Mylan Pharmaceuticals Pvt Ltd, a subsidiary of Mylan N.V. has received marketing authorisation from the Drug Controller General of India (DCGI) for its antiretroviral (ARV) drug Avonza.

Avonza ((TLE400) is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate tablets recommended by the World Health Organization (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS.

Commenting on the launch, Mylan President Rajiv Malik said: "Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs. Mylan is the first to offer this combination in India.’’

In April 2017, the Health Ministry in India launched the Test and Treat Policy for HIV; anyone testing positive for HIV would get antiretroviral therapy irrespective of the CD4 count or clinical stage.

Globally, Mylan supplies life-saving ARVs to nearly 50 per cent of patients being treated for HIV/AIDS in more than 100 developing countries. Its ARV portfolio includes 14 active pharmaceutical ingredients and 50 finished dosage forms in first-line, second-line and paediatric formulations.

Published on August 08, 2017

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor